On the presented X-ray of the skull in the lateral projection, multiple foci of destruction of various sizes and shapes, with clear outlines and boundaries, are visualized. This x-ray picture is observed with multiple myeloma (multiple myeloma).
In this disease, abnormal plasma cells of the bone marrow proliferate, which causes destruction of bone tissue. Clinical manifestations of the disease are due to the defeat of the function of the musculoskeletal system and the development of specific nephropathy.
Distinguish between generalized myelomatosis with multiple bone lesions and single tumors (plasmacytomas). Neoplasms are localized most often in the bones of the skull, ribs, pelvis, shoulder blades and vertebrae. In the long tubular bones of the extremities (in the proximal parts of the femur and humerus), myeloma rarely develops.
Treatment for this cancer includes chemotherapy, radiation therapy, interferon medication, bone marrow transplantation, and plasmapheresis.
The prognosis of the disease depends on the stage: when stage 3 is detected, 10-25% of patients survive for 5 years, with stage 2 - about 40%.
Content
On the presented X-ray of the skull in the lateral projection, multiple foci of destruction of various sizes and shapes, with clear outlines and boundaries, are visualized. This x-ray picture is observed with multiple myeloma (multiple myeloma).
In this disease, abnormal plasma cells of the bone marrow proliferate, which causes destruction of bone tissue. Clinical manifestations of the disease are due to the defeat of the function of the musculoskeletal system and the development of specific nephropathy.
Distinguish between generalized myelomatosis with multiple bone lesions and single tumors (plasmacytomas). Neoplasms are localized most often in the bones of the skull, ribs, pelvis, shoulder blades and vertebrae. In the long tubular bones of the extremities (in the proximal parts of the femur and humerus), myeloma rarely develops.
Treatment for this cancer includes chemotherapy, radiation therapy, interferon medication, bone marrow transplantation, and plasmapheresis.
The prognosis of the disease depends on the stage: when stage 3 is detected, 10-25% of patients survive for 5 years, with stage 2 - about 40%.